Traumatic Brain Injury Clinical Trial Funded

Psilocybin Assisted Therapy (PAT) is an emerging treatment option that’s attracting growing attention from medical professionals around the world, with preclinical and clinical evidence suggesting benefits in neuroplasticity, emotional processing, and a reduction in symptoms.

Here in Aotearoa, Tū Wairua is at the forefront of this field; a research initiative developing a culturally-appropriate approach to the therapeutic use of indigenous psilocybin-containing mushrooms. 

Until now, the project's focus has been on treating problematic methamphetamine use. But as interest in PAT grows, so too does the scope of Tū Wairua.

The Tū Wairua collective has received Health Research Council funding for a clinical trial exploring whether PAT can help reduce symptoms of mild Traumatic Brain Injury (TBI) in sportspeople. The study will recruit adults experiencing persistent mild TBI symptoms into a structured therapeutic pathway grounded in a marae-based framework. The pathway will include preparation, a single PAT session, and supported integration following the treatment.

Cross-sectoral collaboration is integral to this kaupapa, with Mātai Medical Research Institute providing biomedical insights and Rua Bioscience contributing our expertise to the cultivation, medicine manufacturing and regulatory aspects.

For our part, involvement in Tū Wairua enables us to advance company aspirations for our community and the innovative health solutions for people everywhere. We are buoyed by the growing momentum behind new therapeutic pathways using natural products in clinical contexts and are excited to be a part of the movement.